Table 3.

The reported outcomes of the included studies regarding the infection risk and severity of disease among prostate cancer patients who received ADT compared to who did not receive ADT

Study/year/country	Infection risk for ADT	Disease severity
Klein et al. 2021, United State [19]	OR: 0.9; 95% CI 0.54–1.61, p = 0.8	Sample size limitations
Montopoli et al. 2020, Italy [20]	OR: 4.05; 95% CI; 1.55–10.59, p = 0.0043	OR: 4.40; CI 0.76–25.50, p = 0.0982
Koskinen et al. 2020, Finland [16]	OR: 0.88; 95% CI 0.32–2.44, p = 0.81	OR: 0.53; 95% CI 0.04–6.66, p = 0.63
Kwon et al. 2020, United State [17]	OR: 1.30; 95%CI 0.78–2.19, p = 0.31	OR: 0.56, 95% CI 0.07–4.88, p = 0.60
Patel et al. 2020, United State [18]	N/A	Death, OR: 0.37; 95% CI 0.08–1.80, p = 0.220
		Intubation, OR: 0.31; 95%CI 0.05–1.81, p=0.192
	N/A	Overall survival, HR 1.28; 95% CI 0.79–2.08, p = 0.32
		Intubation, HR 1.07; 95% 0.51–2.23, p = 0.87

ADT androgen deprivation therapy, OR odds ratio, HR hazard ratio